Acadia Pharmaceuticals stock unchanged as BofA maintains Neutral rating

Acadia Pharmaceuticals (NASDAQ:ACAD) announced the discontinuation of its Phase 3 Prader-Willi syndrome drug candidate, ACP-101, following its failure to meet primary and secondary endpoints. While BofA Securities maintained a Neutral rating on Acadia, focusing on the Daybue launch and other pipeline assets, this clinical setback significantly benefits competitor Soleno Therapeutics by removing a competitive overhang for its Vykat drug in the PWS treatment space, prompting positive reiterations from analysts like Wells Fargo and Stifel.

Analysis

Acadia Pharmaceuticals (ACAD) has announced a significant clinical setback with the failure of its Phase 3 COMPASS PWS study for ACP-101 in Prader-Willi syndrome (PWS). The drug candidate did not achieve statistical significance on its primary or secondary endpoints, leading management to discontinue its development. Analyst reaction to ACAD has been mixed but largely unsurprised; BofA Securities maintained its Neutral rating and $27.00 price target, noting it had already viewed the trial as a high-risk "upside call option" and had not included the program in its valuation models. This sentiment is echoed by Stifel's Hold rating, while Baird remains more optimistic with an Outperform rating and $31.00 target. The investment thesis for Acadia, which had seen a 37% stock gain in the prior six months, now rests more heavily on the reacceleration of its Daybue launch for Rett syndrome and future prospects like ACP-204 in Alzheimer’s disease psychosis. Conversely, this failure directly benefits competitor Soleno Therapeutics (SLNO), as it removes a key competitive overhang for its PWS drug, Vykat. This positive development for Soleno is reflected in reaffirmed analyst ratings, including an Overweight from Wells Fargo with a $123.00 price target and a Buy from Stifel with a $118.00 target, highlighting a clear strategic shift in the PWS treatment landscape.

Key Decisions for Investors

• Investors in Acadia Pharmaceuticals (ACAD) should re-evaluate their positions based on the commercial performance of Daybue and the potential of the remaining pipeline, as the Prader-Willi syndrome catalyst is now eliminated.
• The failure of Acadia's trial significantly de-risks the commercial path for Soleno Therapeutics' (SLNO) Vykat, presenting a strengthened bull case for investors considering exposure to the PWS treatment market.
• Consider the potential for a pair trade, going long Soleno Therapeutics (SLNO) and short Acadia Pharmaceuticals (ACAD), to capitalize on the divergent outcomes stemming from this single clinical event.